ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2026
Risk of influenza and COVID-19 illness and pediatric obstructive sleep apnea: a TriNetX cohort with 5-year follow-up.
Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea (OSA) is associated with impaired immune responses. Prior small-scale investigations suggested that pediatric OSA leads to a more severe clinical course of common childhood viruses. Whether OSA increases the risk of infection remains unknown.
objectivesTo examine whether children with OSA are at increased risk of influenza or COVID-19, and to assess the effect of adenotonsillectomy.
methodsUsing TriNetX, we compared children aged 2-18 years with incident OSA and matched controls without OSA. Outcomes were ICD-10-coded influenza and COVID-19 over a five-year follow-up. We estimated risk ratios (RRs) and Kaplan-Meier hazard ratios (HRs).
resultsMatched cohorts included 539,127 children each (mean age 5.6 ± 3.6 years). Influenza was diagnosed in 5.1% of OSA vs. 2.8% of controls (RR 1.80; 95% CI, 1.765-1.836); five-year influenza-free survival was 90.27% vs. 93.04% (HR 1.45; 95% CI, 1.421-1.479). COVID-19 was diagnosed in 2.5% vs. 1.0% (RR 2.496; 95% CI, 2.418-2.576); five-year COVID-19-free survival was 95.02% vs. 97.49% (HR 1.986; 95% CI, 1.924-2.050). Effects were similar across age groups. In the treatment sub-analysis (n = 96,004 per group), adenotonsillectomy did not reduce risk. In secondary analyses, OSA was also associated with a higher risk of pneumonia due to influenza or COVID-19.
conclusionsIn a period spanning 5 years after OSA diagnosis, children of all ages have a significantly higher risk of influenza and COVID-19 diagnoses. Although absolute risks are low, adenotonsillectomy does not lessen susceptibility, suggesting persistent immune dysregulation and supporting prioritization of seasonal vaccination in children with OSA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.